TransMedics Group Stock (NASDAQ:TMDX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$113.21

52W Range

$88.50 - $156.00

50D Avg

$120.37

200D Avg

$122.96

Market Cap

$3.83B

Avg Vol (3M)

$901.40K

Beta

2.08

Div Yield

-

TMDX Company Profile


TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

728

IPO Date

May 02, 2019

Website

TMDX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Service Revenue$233.09M$167.67M$65.55M
Product$372.40M$273.87M$176.05M

Fiscal year ends in Dec 25 | Currency in USD

TMDX Financial Summary


Dec 25Dec 24Dec 23
Revenue$605.49M$441.54M$241.62M
Operating Income$108.58M$37.50M$-28.73M
Net Income$190.29M$35.46M$-25.03M
EBITDA$108.58M$69.95M$-7.70M
Basic EPS$5.60$1.07$-0.77
Diluted EPS$4.87$1.01$-0.77

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Feb 25, 26 | 4:30 PM
Q3 25Oct 29, 25 | 4:30 PM
Q2 25Jul 31, 25 | 4:30 PM

Peer Comparison


TickerCompany
HNGEHinge Health, Inc.
OSCROscar Health, Inc.
KYMRKymera Therapeutics, Inc.
BRKRBruker Corporation
NAMSNewAmsterdam Pharma Company N.V.
GKOSGlaukos Corporation
OPCHOption Care Health, Inc.
AKROAkero Therapeutics, Inc.
IMVTImmunovant, Inc.